The EMA’s risk assessment committee recommended restrictions on the use of the broad-spectrum antibiotics.

The FDA approved Biktarvy, Gilead’s once-daily, triple-combo tablet for treating HIV infection, paving the way for the biotech company to capture more of the multibillion-dollar HIV drug market.

The U.S. Food and Drug Administration approved the first two-drug regimen to treat HIV, aimed at lessening the side effect burden of current treatments that combine three or four medicines.

Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug.

An HIV drug approved less than 3 years ago is to be rolled out in Botswana as a core medicine for newly diagnosed patients.